(1-6)-Alpha-glucomannan
CAS 37220-17-0
(1-6)-Alpha-glucomannan (CAS 37220-17-0) is a pharmaceutical compound with 0 bioactivity targets and 48 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
(1-6)-Alpha-glucomannan is linked to DTXSID201020079 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is (1-6)-Alpha-glucomannan used for in pharmaceutical contexts?
(1-6)-Alpha-glucomannan (CAS 37220-17-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for (1-6)-Alpha-glucomannan?
(1-6)-Alpha-glucomannan has 48 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain upper, Constipation, Cough, Diarrhoea, Dizziness. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is (1-6)-Alpha-glucomannan also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Konjac Glucomannan with EU status "permitted".
What clinical phase is (1-6)-Alpha-glucomannan in?
No phase 1-4 clinical development badge is rendered for (1-6)-Alpha-glucomannan because the matched compound identifier rows do not contain a max-phase value.